Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918262 | 0.85 | MEN1 (0.51) | EPHX2MEN1KMT2A | |
| SCHEMBL21397003 | 0.83 | GRIN2D (0.50) | EPHX2MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL10755394 | 0.81 | GRIN2D (0.52) | EPHX2MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL10755449 | 0.80 | GRIN2D (0.50) | EPHX2MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL10759013 | 0.80 | GRIN2D (0.50) | EPHX2MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL1010509 | 0.79 | EPHX2 (0.47) | EPHX2MEN1KMT2AGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL1677979 | 0.76 | GRIN2D (0.52) | EPHX2MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL1677869 | 0.76 | MEN1 (0.51) | EPHX2MEN1KMT2AGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL1677813 | 0.75 | EPHX2 (0.50) | EPHX2MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL27599314 | 0.75 | EPHX2 (0.54) | EPHX2MEN1KMT2AGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101597196-B | Improved drug candidate and preparation method thereof | JIYAKETA CO., LTD. (CH) | 2016-05-04 | — | — | CN | disclosed |
| EP-1646659-B1 | METHOD FOR THE PREPARATION OF 1,3-PROPANE DISULFONIC ACID COMPOUNDS | KIACTA S RL (CH) | 2014-05-14 | — | — | EP | disclosed |
| US-20110021813-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | KONG XIANQI | 2011-01-27 | — | — | US | disclosed |
| CN-101597196-A | Improved drug candidate and preparation method thereof | BELLUS HEALTH INTERNAT LTD (CH) | 2009-12-09 | — | — | CN | disclosed |
| CN-100528840-C | Improved drug candidates and methods for their preparation | NEUROCHEM INTERNAT LTD (CH) | 2009-08-19 | — | — | CN | disclosed |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-31 | — | — | US | disclosed |
| US-7253306-B2 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-07 | — | — | US | disclosed |
| CN-1839117-A | Improved drug candidates and methods for their preparation | NEUROCHEM INTERNAT LTD (CH) | 2006-09-27 | — | — | CN | disclosed |
| EP-1646659-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | Neurochem (International) Limited (CH) | 2006-04-19 | — | — | EP | disclosed |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-06-30 | — | — | US | disclosed |
| WO-2004113391-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021813-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | MPST, TTR, STS | EPHX2 2293/4885MEN1 1137/4885KMT2A 4395/4885 |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | MPST, TTR, STS | EPHX2 2293/4885MEN1 1137/4885KMT2A 4395/4885 |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | MPST, TTR, STS | EPHX2 2293/4885MEN1 1137/4885KMT2A 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.